The efficacy and adverse effects of budesonide in remission induction treatment of autoimmune hepatitis: a retrospective study.
CONCLUSIONS: This study showed no differences in biochemical response between the groups. Lower, although not significantly, rate of adverse effects and lower total number of adverse effects indicate that BUD/AZA may potentially be used as the first-line treatment of choice, especially in patients with obesity, diabetes, resistant hypertension, glaucoma, or osteoporosis.
PMID: 31483120 [PubMed - in process]
Source: Croatian Medical Journal - Category: General Medicine Authors: Binicier OB, Günay S Tags: Croat Med J Source Type: research
More News: Croatia Health | Diabetes | Eating Disorders & Weight Management | Endocrinology | General Medicine | Glaucoma | Hepatitis | Hepatitis A | Hypertension | Obesity | Orthopaedics | Osteoporosis | Prednisolone | Study